Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.74 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403347 | 1.00 | AR (0.74) | ARSRD5A2KCNH2 | |
| SCHEMBL5874196 | 1.00 | AR (0.74) | ARSRD5A2KCNH2 | |
| SCHEMBL5116733 | 0.91 | AR (0.74) | ARSRD5A2KCNH2 | |
| SCHEMBL14013760 | 0.91 | AR (0.74) | ARSRD5A2KCNH2 | |
| SCHEMBL7615006 | 0.90 | AR (0.72) | ARSRD5A2KCNH2 | |
| SCHEMBL7614998 | 0.90 | AR (0.72) | ARSRD5A2KCNH2 | |
| SCHEMBL8150406 | 0.89 | AR (0.67) | ARSRD5A2KCNH2 | |
| SCHEMBL5247468 | 0.88 | AR (0.58) | ARSRD5A2KCNH2 | |
| SCHEMBL5339929 | 0.88 | AR (0.58) | ARSRD5A2KCNH2 | |
| SCHEMBL8410044 | 0.88 | AR (0.70) | ARSRD5A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622567-B1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-7351698-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351698-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1420796-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-RE39056-E1 | 4-Azasteroids for treatment of hyperandrogenic conditions | MERCK & CO, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1420796-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| EP-0484094-B1 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO CO (JP) | 1996-06-26 | — | — | EP | disclosed |
| EP-0468012-B1 | 17$g(b)-SUBSTITUTED-4-AZA-5$g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA SPA (IT) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994022900-A1 | AZA-ANDROSTANE-17β-CARBOXAMIDES | CIBA-GEIGY AG (CH) | 1994-10-13 | — | — | WO | disclosed |
| US-5304562-A | Inhibitors of 5-alpha-reductase; treating prostate disorders | CIBA-GEIGY CORPORATION (US) | 1994-04-19 | — | — | US | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0538192-A1 | New 17-beta-substituted aza-androstanderivatives | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | disclosed |
| US-5155107-A | Inhibiting androgen action, anticarcinogenic agents, treating skin disorders, baldness | FARMITALIA CARLO ERBA (IT) | 1992-10-13 | — | — | US | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
| EP-0468012-A1 | 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION. | ERBA CARLO SPA (IT) | 1992-01-29 | — | — | EP | disclosed |
| US-4220775-A | Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors | MERCK & CO., INC. (US) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | AR, FSHR, SHBG | AR 1/4885SRD5A2 80/4885KCNH2 4717/4885 |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | SHBG, FSHR, AR | AR 3/4885SRD5A2 57/4885KCNH2 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.